Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 549-556

  Capel, Emilie ^a,b   Auclair, Martine ^a,b   Caron Debarle, Martine ^a,b   Capeau, Jacqueline ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ATAZANAVIR; DARUNAVIR; GLUCOSE; LOPINAVIR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RITONAVIR;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INSULIN SENSITIVITY; LIPOLYSIS; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; HIV PROTEASE INHIBITORS; HUMANS; INSULIN RESISTANCE; LIPOLYSIS; LOPINAVIR; MICE; MITOCHONDRIA; OLIGOPEPTIDES; PYRIDINES; REACTIVE OXYGEN SPECIES; RITONAVIR; SULFONAMIDES;

EID: 84861659153     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1988     Document Type: Article

References (24)

1. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
2. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
3. Mallon PW. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies. Curr Opin HIV AIDS 2007; 2:282-292. (Pubitemid 46941820)
4. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144. (Pubitemid 39463678)
5. Tomaka F, Lefebvre E, Sekar V, et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 2009; 10:318-327.
6. Collot-Teixeira S, De Lorenzo F, Waters L, et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther 2009; 85:375-378.
7. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821. (Pubitemid 44358899)
8. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010; 16:218-229.
9. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 106LB.
10. Valantin MA, Flandre P, Kolta S, et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with CDRV/r monotherapy vs 2 NRTI + DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 721.
11. Boccara F, Auclair M, Cohen A, et al. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther 2010; 15:363-375.
12. de Jesus E, Ortiz R, Khanlou H. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARVtreatment-naive HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract H718B.
13. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004; 75:310-323. (Pubitemid 38471556)
14. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096. (Pubitemid 38691603)
15. Caron M, Auclair M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 2008; 13:27-38. (Pubitemid 351541671)
16. Walker UA, Auclair M, Lebrecht D, et al. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11:25-34.
17. Leclercq P, Goujard C, Allaert F, et al. Prevalence of lipodystrophy among patients on antiretroviral therapy for up to 10 years. A French observational study. Antivir Ther 2010; 15 Suppl 4:A38.
18. Kim MJ, Leclercq P, Lanoy E, et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 2007; 12:1273-1283.
19. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006; 42:273-280. (Pubitemid 43054203)
20. Horban A. HArribas J, Hill A, van Delft Y, Moecklinghoff C. Anthropometric sub-study of the MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA<50 copies/ml at screening. Antivir Ther 2010; 15 Suppl 4:A36.
21. Tebas P, Sax P, Aberg J, et al. METABOLIK (Metabolic Evaluation in Treatment-naives Assessing the impact of two Boosted protease inhibitors on LIpids and other markers): week 48 comparison of body fat changes in ARV-naive subjects receiving darunavir/ritonavir- or atazanavir/ritonavir-based therapy. Antivir Ther 2010; 15 Suppl 4:A39.
22. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12:489-500. (Pubitemid 47041147)
23. Jones SP, Waitt C, Sutton R, Back DJ, Pirmohamed M. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS 2008; 22:1293-1298.
24. Hruz PW, Yan Q, Tsai L, et al. GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy rodent model system. Antimicrob Agents Chemother 2011; 55:1377-1382.